Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yuhan Corporation
This trial is a phase 3 study to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.
In "Temisartan/Amlodipine/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine/Rosuvastatin" 8 for weeks.
In "Temisartan/Amlodipine" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Amlodipine" for 8 weeks.
In "Temisartan/Rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "Temisartan/Rosuvastatin" for 8 weeks.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Signed informed consent
2. Subjects with hypertension and hyperlipidemia
You may not be if
1. Patients with known or suspected secondary hypertension